METHODS FOR ADMINISTERING ANTI-IL-5 ANTIBODIES

PROBLEM TO BE SOLVED: To provide pharmaceutical compositions for treating hypereosinophilic syndrome.SOLUTION: A pharmaceutical composition of the invention comprises an anti-IL-5 antibody and a pharmaceutically acceptable carrier, where the anti-IL-5 antibody comprises a heavy chain of a specified sequence and a light chain of another specified sequence, and the composition is administered to a human patient so as to provide a mean maximum plasma concentration of the anti-IL-5 antibody of from 1.03±0.21 to 278±29 μg/mL, preferably from 12.1±2.4 to 278±29 μg/mL, more preferably from 34.1±12.1 to 38.2±9.1 μg/mL, and an Area Under the Curve (AUC (0-inf)) of from 15.5±2.7 to 4361±168 μg/day/mL, preferably, from 207±34 to 4361±168 μg/day/mL, more preferably from 1110±372 to 1196±254 μg/day/mL.SELECTED DRAWING: None 【課題】ヒト患者における過好酸性症候群を治療するための医薬組成物の提供。【解決手段】抗ＩＬ−５抗体及び医薬上許容される担体又は賦形剤を含有する医薬組成物であって、抗ＩＬ−５抗体が特定の配列を含有する重鎖と、他の特定の配列を含有する軽鎖を含んでおり、ヒト患者へ１．０３±０．２１〜２７８±２９μｇ／ｍＬ、好ましくは１２．１±２．４〜２７８±２９μｇ／ｍＬ、特に好ましくは、３４．１±１２．１〜３８．２±９．１μｇ／ｍＬの抗ＩＬ−５抗体の平均最大血漿濃度、１５．５±２．７〜４３６１±１６８μｇ／日／ｍＬ、好ましくは２０７±３４〜４３６１±１６８μｇ／日／ｍＬ、特に好ましくは１１１０±３７２〜１１９６±２５４μｇ／日／ｍＬの曲線下面積（ＡＵＣ（０−ｉｎｆ））となるよう投与される、医薬組成物。【選択図】なし